WeChat Share

Details

 

CABA Expert Forum:Immuno Oncology Therapy

美中生物医药协会专家论坛:肿瘤免疫治疗 

 

2017年3月18,礼拜六上午9-12点,美中生物医药协会(CABA) 将在哈佛大学丹娜法伯癌症研究所举办一个以肿瘤免疫治疗(Immuno-Oncology Therapy) 为主题的专家论坛和沙龙活动. 形式主要以圆桌讨论和解答问题为主,嘉宾讲座为辅,将会覆盖肿瘤免疫的几大方向:比如 small molecule,biologics and cell therapy;CART, checkpoint inhibitors, DC vaccine 等等. 活动目的在于提供给对此领域感兴趣的朋友一个和专家面对面交流和探讨的机会. 活动完全免费. 因位置有限,请速速报名. 欢迎您将感兴趣的话题或疑问发到我们的信箱:truelancao@gmail.com


Time: 9:00 AM – 12:00 PM03/18/2017 (Saturday)

Address: Dana-Farber Cancer Institute, DANA 1620, 450 Brookline Ave, Boston


Presented by: 

Chinese-American BioMedical Association (CABA) 美中生物医药协会

 

Event Organizing Committee

 Chairs

Lan Cao (CABA)

 Cochairs

Yu Qian (Harvard CSSA)

Committee

TBA

 Contact: truelancao@gmail.com

 

 

Confirmed Panelists

 

Yangbing Zhao, MD, Ph.D,

Director

TCEL Abramson Family Cancer Research Institute

Depatment of Pathology & Laboratory Medicine, the University of Pennsylvania Perelman School of Medicine


Wenru Song, MD, Ph.D,

Co-founder

Kira Therapeutics, a new startup based on cutting-edge immunological sciences

     

                                     

 

Panelists

Yangbing Zhao, PhD
University of Pennsylvania, Director
Dr. Yangbing Zhao is the Director of the T Cell Engineering Laboratory (TCEL), Center for Cellular Immunotherapies at the University of Pennsylvania, working closely with Dr. Carl June. He received an MD and PhD in Immunology from the Third Medical University in Chongqing, China. Prior to UPenn, Dr. Zhao has worked at The Weizmann Institute of Science, Duke University Medical Center, and NCI working with Dr. Steven Rosenberg. Dr. Zhao's research work at NCI directly led to clinical trials of treating cancer patients with TCR or CAR engineered T cells against NY-ESO-1, Her2/Neu, CD19 or VEGFR. Dr. Zhao's Laboratory’s research and development work at UPenn has led to multiple clinical trials for the treatment of solid tumors with genetically engineered T cells against mesothelioma, pancreatic cancer, breast cancer and glioblastoma.
Wenru Song, MD, PhD
Kira Therapeutics, Co-founder
Dr. Song is a physician-scientist-turned entrepreneur and is the co-founder of Kira Therapeutics, a new biotech startup based on cutting-edge immunological sciences. Dr. Song was most recently as the global VP and global clinical leader of Immuno-Oncology development at AstraZeneca Global Medicines Development where he initially led the Asia Pacific immune-oncology (IO) development and later led the global program for IO combinations and IO new indications. Previously, Dr. Song was the Head of Regional Oncology Development in Asia-Pacific at Millennium: The Takeda Oncology Company where he had led the building of Takeda’s regional oncology development infrastructure and oncology clinical development. Prior to joining Millennium, Dr. Song was a medical director/clinical lead at Pfizer Oncology where he led a number of cancer immunotherapy and antibody-drug conjugate (ADC) programs. Before joining the pharma-industry in 2008, he was an associate investigator at Baylor Institute of Immunology Research and an attending oncologist at Baylor Sammons Cancer Center in Dallas. He studied Medicine at Shandong University in China before coming to the US for his PhD study in Immunology. He then did a postdoctoral fellowship in cancer immunotherapy with Dr. Ron Crystal at Cornell University Medical Center, followed by medical residency training at Montefiore Medical Center/Albert Einstein College of Medicine, and clinical oncology fellowship at Stanford University where he also performed research on cancer immunotherapy with Drs. Ron Levy and Ed Engleman.

Registration

Type Sales End Price Quantity

CABA member

2017-03-18 12:00 $0

non-CABA member, student

2017-03-18 12:00 $0

non-CABA member

2017-03-18 12:00 $0

About CABA

Chinese-American BioMedical Association (CABA) is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development. As the majority of its members are scientists with Chinese heritage, CABA will operate in two important areas. One is to serve as a platform for its members to develop and advance their careers in the US pharmaceutical and biomedical industry, the other is to serve as a bridge to connect members including corporate members with the scientific and business resources in China thus facilitating collaboration between the pharmaceutical and biomedical industries across continents. To fulfill these goals, we will organize scientific and business symposia, conferences, workshops, in US and China, as well as social events to promote networking and communication among members. We will bring together members, scientists, professionals, government officials and business leaders across the continents under a collaborative environment and achieve their best potentials. 

CABA is a volunteer-based society. We rely on members to contribute their time and efforts to build the organization. We rely on corporate members and sponsors to raise fund to support the above activities. We value integrity, honesty, professionalism, community service, scientific excellence, responsibility and accountability. We invite you to explore our organization, and we are confident you will share our values and are interested in becoming a member, devoting your time or efforts, or sponsoring CABA activities. In summary, CABA is built by its members and serves for its members.


www.cabaweb.org


Contact Us

Your Name: *
Your Email: *
Cell phone:
Subject: *
Message: *